Table 2.

Demographics, disease characteristics, grade of axonal damage, and European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) criteria of all subgroups.

	Typical CIDP		DADS		Diabetic		Oxaliplatin induced		Idiopathic neuropathy
	(n = 67)		(n = 28)		neuropathy		induced		associated with restless
					neuropathy (n = 40)		legs syndrome (n = 12)		(n = 30)
Gender, male/female	54/22		26/2		19/21		7/5		10/20
Age at examination, mean, SD	59	±13	60	±11	68	±11	65	±6	64	±18
Disease duration from diagnosis until examination (months), median, range	31	0–295	21	0–118	128	3–366	1	0–5	89	0–397
INCAT-ODSS at time of examination, median, range	2	0–9	2	0–6	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Grade of axonal damage *, n, %
Slight	10	15%	2	7%	7	18%	5	42%	10	33%
Moderate	34	51%	19	68%	19	48%	6	50%	12	40%
Severe	18	27%	7	25%	7	18%	1	8%	6	20%
No amplitudes detectable	5	8%	0	0%	7	18%	0	0%	1	3%
EFNS/PNS criteria at timepoint of ultrasound examination, n, %
Not fulfilled	17	25%	4	14%	29	73%	9	75%	19	63%
Possible	16	24%	7	25%	10	25%	2	17%	11	37%
Probable	10	15%	7	25%	1	3%	1	8%	0	0%
Definite	24	36%	10	36%	0	0%	0	0%	0	0%

INCAT-ODSS, inflammatory neuropathy cause and treatment overall disability score.

^*Grading of axonal damage.

Slight axonal damage: 71 to <100 % of the lower limit of the reference amplitude.

Moderate axonal damage: 41–70 % of the lower limit of the reference amplitude.

Severe axonal damage: 11–40 % of the lower limit of the reference amplitude.

No CMAP or SNAP amplitude detectable: <10 % of the lower limit of the amplitude of the reference values.